Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Melander

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Lakartidningen|March 4, 2005
[Selective reporting--greater problem than selective publishing?]Hans Melander
Lakartidningen|June 3, 2009
[Meta-analyses uncertain basis for first choice antidepressive agents]Hans Melander
Lakartidningen|February 8, 2011
[Medical Product Agency about Multiferon: positive benefit-risk relation]Bertil Jonsson, Hans Melander
Lakartidningen|January 25, 2008
[Treatment of depression in children and adolescents: SSRI can/should be used after individual assessment]Hans Melander, Jane Ahlqvist Rastad
Lakartidningen|July 15, 2006
[Uneven sex distribution in the cardiovascular trials--an exaggerated problem]Hans Melander, Jane Ahlqvist Rastad
European Journal of Clinical Pharmacology|November 15, 2007
The conscientious judgement of a DSMB--statistical stopping rules re-examinedKarin Hedenmalm, Hans Melander, Gunnar Alvan
BMJ (Clinical Research Ed.)|May 31, 2003
Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applicationsHans Melander, Jane Ahlqvist-Rastad, Gertie Meijer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 16, 2008
A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressantsHans Melander, Tomas Salmonson, Eric Abadie, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Lakartidningen|March 4, 2005
[Selective reporting--greater problem than selective publishing?]Hans Melander
Lakartidningen|June 3, 2009
[Meta-analyses uncertain basis for first choice antidepressive agents]Hans Melander
Lakartidningen|February 8, 2011
[Medical Product Agency about Multiferon: positive benefit-risk relation]Bertil Jonsson, Hans Melander
Lakartidningen|January 25, 2008
[Treatment of depression in children and adolescents: SSRI can/should be used after individual assessment]Hans Melander, Jane Ahlqvist Rastad
Lakartidningen|July 15, 2006
[Uneven sex distribution in the cardiovascular trials--an exaggerated problem]Hans Melander, Jane Ahlqvist Rastad
European Journal of Clinical Pharmacology|November 15, 2007
The conscientious judgement of a DSMB--statistical stopping rules re-examinedKarin Hedenmalm, Hans Melander, Gunnar Alvan
BMJ (Clinical Research Ed.)|May 31, 2003
Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applicationsHans Melander, Jane Ahlqvist-Rastad, Gertie Meijer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 16, 2008
A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressantsHans Melander, Tomas Salmonson, Eric Abadie, et al.
Pageof 1